

## **SUMMARY OF PRODUCT CHARACTERISTICS**

### **1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

AquaVac 6 emulsion for injection for Atlantic salmon

### **2. QUALITATIVE AND QUANTITATIVE COMPOSITION**

Each dose of 0.1 ml contains:

#### **Active substances:**

Infectious pancreatic necrosis virus (IPNV) serotype Sp, inactivated  $\geq 1.5$  ELISA units<sup>1</sup>

*Aeromonas salmonicida* subsp. *salmonicida*, inactivated  $\geq 10.7 \log_2$  ELISA units<sup>2</sup>

*Vibrio salmonicida*, inactivated  $\geq 90\%$  RPS<sup>3</sup>

*Listonella (Vibrio) anguillarum* serotype O1, inactivated  $\geq 75\%$  RPS<sup>3</sup>

*Listonella (Vibrio) anguillarum* serotype O2a, inactivated  $\geq 75\%$  RPS<sup>3</sup>

*Moritella viscosa*, inactivated  $\geq 6.5 \log_2$  ELISA units<sup>2</sup>

<sup>1</sup> Antigenic mass measured in the final product

<sup>2</sup> Serological response in Atlantic salmon

<sup>3</sup> RPS: relative percentage survival in a laboratory test in Atlantic salmon

#### **Adjuvant:**

Paraffin, light liquid: 43 mg.

For the full list of excipients, see section 6.1.

### **3. PHARMACEUTICAL FORM**

Emulsion for injection.

White to nearly white emulsion.

### **4. CLINICAL PARTICULARS**

#### **4.1 Target species**

Atlantic salmon (*Salmo salar* L).

#### **4.2 Indications for use, specifying the target species**

For active immunisation of Atlantic salmon to reduce mortality caused by infections with IPNV (infectious pancreatic necrosis), *Aeromonas salmonicida* subsp. *salmonicida* (furunculosis), *Vibrio salmonicida* (cold-water vibriosis), *Listonella (Vibrio) anguillarum* serotype O1 and O2a (vibriosis), and *Moritella viscosa* (winter ulcer disease).

Onset of immunity:

500 degree days after vaccination for the bacterial antigens and 608 degree days after vaccination for IPNV.

Duration of immunity:

*A. salmonicida* and *M. viscosa*: 18 months.

*L. anguillarum* O1, *L. anguillarum* O2a and *V. salmonicida*: 16 months.

Infectious pancreatic necrosis virus: 4 months.

#### **4.3 Contraindications**

None.

#### **4.4 Special warnings for each target species**

Vaccinate healthy fish only.

#### **4.5 Special precautions for use**

##### Special precautions for use in animals

The vaccine should not be used in diseased or unhealthy fish, fish receiving medical treatment, or fish during smoltification.

Do not vaccinate below 2.5 °C or above 17 °C.

Vaccination at high water temperatures ( $\geq 17$  °C) may increase local reactions.

Incorrect vaccination, stress and poor hygiene may lead to increased side effects.

##### Special precautions to be taken by the person administering the veterinary medicinal product to animals

Personal protective equipment consisting of guarded needles or needle protectors should be used when administering the product.

In case of accidental self-injection, seek medical advice immediately and show the package leaflet or label to the physician.

To the user:

This veterinary medicinal product contains mineral oil. Accidental injection/self-injection may result in severe pain and swelling, particularly if injected into a joint or finger, and in rare cases could result in the loss of the affected finger if prompt medical attention is not given.

If you are accidentally injected with this product, seek prompt medical advice even if only a very small amount is injected and take the package leaflet with you.

If pain persists for more than 12 hours after medical examination, seek medical advice again.

To the physician:

This veterinary medicinal product contains mineral oil. Even if small amounts have been injected, accidental injection with this product can cause intense swelling, which may, for example, result in ischaemic necrosis and even the loss of a digit. Expert, PROMPT, surgical attention is required and may necessitate early incision and irrigation of the injected area, especially where there is involvement of finger pulp or tendon.

#### **4.6 Adverse reactions (frequency and seriousness)**

Oil adjuvant increases the risk of side effects after vaccination in the form of adhesions and pigmentation in the abdominal cavity. Moderate adhesions and pigmentation in the abdominal cavity are very commonly observed.

Vaccine residues occur very commonly.

Adhesions with a Spielberg score of 1 to 3 are commonly seen with most of the scores  $\leq 2$ . More extensive changes (Spielberg score 4) uncommonly occur.

A reduction in appetite after vaccination is very commonly observed. The loss of appetite is most pronounced during the first week after vaccination and feed intake is restored within 10 - 12 days. Appetite loss after vaccination does not affect weight at harvest.

The frequency of adverse reactions is defined using the following convention:

- very common (more than 1 in 10 animals treated displaying adverse reaction(s))
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).

#### **4.7 Use during pregnancy, lactation or lay**

Do not use in broodstock. The possible effects of vaccination on spawning have not been investigated.

#### **4.8 Interaction with other medicinal products and other forms of interaction**

No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case-by-case basis.

#### **4.9 Amounts to be administered and administration route**

Intraperitoneal use.

Shake the bottle well before use.

**Dosage:** a single dose of 0.1 ml.

**Administration:** intraperitoneally along the central line, approximately 1 pelvic fin length in front of the pelvic fin base in Atlantic salmon.

Vaccination is recommended for fish above 30 grams.

Food should be withheld at least 2 days prior to vaccination.

The fish should be anaesthetised before vaccination.

The length and the diameter of the applied needle should be adapted to the actual fish size. Ensure that the recommended dose is deposited into the abdominal cavity before the needle is withdrawn.

#### **4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary**

Following the administration of a 2X overdose, no reactions other than those described in section 4.6 were observed.

#### **4.11 Withdrawal period(s)**

Zero-degree days.

### **5. IMMUNOLOGICAL PROPERTIES**

Pharmacotherapeutic group: Immunologicals for *Pisces*, inactivated bacterial and viral vaccines for Atlantic salmon.

ATCvet code: QI10AL02.

Stimulates active immunity against infectious pancreatic necrosis, furunculosis, cold-water vibriosis, vibriosis and winter ulcer disease in Atlantic salmon.

### **6. PHARMACEUTICAL PARTICULARS**

#### **6.1 List of excipients**

Paraffin, light liquid  
Polysorbate 80  
Sorbitan monooleate  
Sodium chloride  
Potassium chloride  
Disodium phosphate dihydrate  
Potassium dihydrogen phosphate  
Water for injections

#### **6.2 Major incompatibilities**

Do not mix with any other veterinary medicinal product.

#### **6.3 Shelf life**

Shelf life of the veterinary medicinal product as packaged for sale: 18 months.  
Shelf life after first opening the container: use within the same day.

#### **6.4 Special precautions for storage**

Store and transport refrigerated (2 °C – 8 °C). Do not freeze.

#### **6.5 Nature and composition of immediate packaging**

Polyethylene terephthalate (PET) bottle closed with a rubber stopper and aluminium cap.

Package size: 500 ml (5,000 doses).

**6.6 Special precautions for the disposal of unused veterinary medicinal products or waste materials derived from use of such products**

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal product should be disposed of in accordance with local requirements.

**7. MARKETING AUTHORISATION HOLDER**

MSD Animal Health UK Limited  
Walton Manor, Walton  
Milton Keynes  
Buckinghamshire  
MK7 7AJ

**8. MARKETING AUTHORISATION NUMBER**


Vm 01708/5065

**9. DATE OF FIRST AUTHORISATION**

08 August 2022

**10. DATE OF REVISION OF TEXT**

January 2024

A handwritten signature in black ink, consisting of stylized, overlapping loops and curves, positioned above the approval date.

Approved: 02 April 2024